PeopleBeatingCancer supports an evidence-based integrative approach to cancer care. For most newly diagnosed patients, FDA-approved therapies form the foundation of treatment, while evidence-based complementary therapies may help reduce side effects and improve survivorship.
Click the orange button to the right to learn more.
MGUS Screening: Who Should Be Tested, What the Blood Tests Show, and Why Early Detection Matters. Can screening for monoclonal gammopathy of undetermined significance (MGUS) prevent multiple myeloma? Should everyone be screened, or only people at increased risk?
These questions are more important than ever as researchers learn how to identify early plasma cell disorders, estimate progression risk, and monitor patients before symptoms develop.
MGUS is a generally asymptomatic condition in which abnormal plasma cells produce a monoclonal protein, also called an M-protein. MGUS is not multiple myeloma, and most people diagnosed with MGUS will never develop myeloma.
Yet MGUS is an important precursor condition for multiple myeloma and certain other blood disorders.
The challenge is that detecting MGUS earlier has not yet been proven to reduce mortality in the general population. This is why routine screening of otherwise healthy adults is not currently recommended.
However, research suggests that screening selected higher-risk populations and monitoring people already diagnosed with MGUS may offer important opportunities for earlier diagnosis and improved risk assessment.
I am a long-term survivor of multiple myeloma. My research and experience with evidence-based non-conventional therapies is the reason why I have lived in complete remission from my incurable blood cancer since achieving complete remission in early 1999.
Scroll down the page and post a question or a comment if there’s anything you’d like to know about MGUS, SMM or MM.
MGUS screening means testing someone who does not have a known monoclonal gammopathy to determine whether an abnormal monoclonal protein is present.
MGUS is often discovered incidentally when blood tests are performed for another medical reason.
According to a 2025 review in JAMA Internal Medicine, MGUS affects more than 4% of adults over age 50, although prevalence varies with age and population.
The average risk of progression to multiple myeloma or a related disorder is approximately 0.5%–1% annually, but individual risk varies considerably.
No. Routine MGUS screening is not currently recommended for the general population.
There are several reasons:
Most people with MGUS will never develop multiple myeloma.
There is no established treatment routinely recommended to prevent progression in otherwise uncomplicated MGUS.
Screening can result in anxiety, additional testing, and medical expenses.
Researchers have not yet established that population-wide screening improves overall survival.
However, screening research is investigating whether particular groups might benefit. This distinction is important: Finding MGUS earlier is not necessarily the same as improving long-term outcomes.
Who may benefit from discussing MGUS testing?
Testing may be appropriate when a physician suspects a plasma cell disorder or a related condition.
Examples include:
Unexplained anemia.
Unexplained kidney dysfunction or significant proteinuria.
Persistent, unexplained bone pain or suspicious bone lesions.
Unexplained hypercalcemia.
Peripheral neuropathy when the clinical findings suggest a monoclonal gammopathy.
Findings suggesting AL amyloidosis or another monoclonal gammopathy of clinical significance.
These symptoms do not necessarily indicate MGUS or myeloma. Many have much more common explanations. People with a strong family history of multiple myeloma or related disorders may also wish to discuss their individual risk with a hematologist.
Research has identified higher MGUS prevalence in certain populations, including people of African ancestry and close relatives of patients with multiple myeloma. However, increased risk alone does not mean that routine screening is recommended for every individual in these groups.
A physician may order several complementary laboratory tests.
Test
What it measures
Serum protein electrophoresis (SPEP)
Detects and helps quantify monoclonal proteins
Serum immunofixation (IFE)
Identifies the type of monoclonal protein
Serum free light chains (sFLC)
Measures free kappa and lambda light chains and their ratio
Complete blood count (CBC)
Checks for anemia and other blood-count abnormalities
Creatinine/eGFR
Evaluates kidney function
Calcium
Checks for abnormal calcium levels
The College of American Pathologists recommends SPEP and serum free light chains for initial detection when a monoclonal gammopathy is suspected, with appropriate confirmatory testing.
Urine studies, bone marrow biopsy, and imaging may be appropriate depending on the results and clinical findings. Not everyone with low-risk MGUS needs a bone marrow biopsy or advanced imaging.
One of the most important developments in MGUS research is the Iceland Screens, Treats, or Prevents Multiple Myeloma (iStopMM) study. Researchers screened more than 75,000 adults in Iceland to better understand how commonly MGUS occurs and whether different monitoring approaches improve patient outcomes.
The study identified thousands of previously unrecognized MGUS cases. Participants diagnosed through screening were assigned to different follow-up strategies, allowing researchers to study the effects of more intensive surveillance.
The early findings showed that more intensive monitoring identifies additional cases of smoldering myeloma and other plasma cell disorders. However, detecting more cases does not by itself prove that screening improves survival.
Additional research from iStopMM has also helped clarify the relationships between MGUS and other health conditions.
What about screening people at increased risk?
The PROMISE study in the United States was designed to investigate monoclonal gammopathies in populations at increased risk of multiple myeloma, including Black adults and people with close relatives affected by certain blood disorders.
The research has helped investigators understand the prevalence of monoclonal proteins and explore improved detection methods.
The study has completed enrollment for first-time screening, although follow-up research continues.
The potential value of screening higher-risk individuals remains an active area of research.
What happens after an MGUS diagnosis?
For most patients, the immediate next step is not treatment. It is accurate diagnosis, risk assessment, and appropriate follow-up. Physicians commonly evaluate three established MGUS progression-risk factors:
The type of monoclonal protein, particularly whether it is IgG or non-IgG.
The concentration of M-protein.
Whether the serum free light chain ratio is abnormal.
The patient’s symptoms, kidney function, blood counts, and other clinical findings also matter.
Low-risk patients may require relatively limited follow-up after initial reassessment, while higher-risk patients may need additional testing and closer monitoring. Research continues to refine these categories, including newer methods for interpreting free light chain results.
Can nutrition, supplements, and lifestyle prevent MGUS from becoming multiple myeloma?
This is the question that interests me most as a long-term multiple myeloma survivor. I believe patients should understand both conventional medical care and the research investigating evidence-based complementary therapies.
Research has examined relationships between MGUS, obesity, physical activity, smoking, sleep, and other potentially modifiable factors. For example, the PROMISE study identified associations between obesity and MGUS prevalence, while higher physical activity was associated with a lower likelihood of certain monoclonal gammopathies.
However, these findings do not establish that changing these behaviors prevents progression from MGUS to multiple myeloma.
Similarly, laboratory and small clinical studies have investigated curcumin and other compounds for their biological effects on plasma cells and monoclonal proteins.
There is currently insufficient clinical evidence to conclude that curcumin, other supplements, or specific foods reliably prevent MGUS progression to multiple myeloma.
That does not make the research unimportant. It means patients need to distinguish promising laboratory findings from proven clinical outcomes. A nutritious diet, appropriate physical activity, weight management, avoiding tobacco, and adequate sleep remain worthwhile for general health.
Supplement use should be discussed with a healthcare professional, particularly when medications, kidney disease, bleeding risk, or other health conditions are involved.
Evidence ratings describe the strength of available evidence for the specific claim, not an endorsement of a treatment.
Five questions to ask your hematologist
If you have been diagnosed with MGUS, consider asking:
What type of MGUS do I have, and what is my estimated risk of progression?
What are my M-protein concentration and serum free light chain ratio?
Do I need additional testing, imaging, or a bone marrow biopsy?
How frequently should my blood tests be repeated?
Are there symptoms or laboratory changes that should prompt earlier evaluation?
These questions can help you participate more actively in your care without assuming that every MGUS diagnosis will eventually become cancer.
My perspective as a multiple myeloma survivor
When I originally wrote about MGUS screening, I questioned the value of identifying a condition that conventional oncology generally does not treat. I still believe that identifying a medical risk should lead to useful information and appropriate action.
But my interpretation of the research has evolved. MGUS screening is not simply about finding a precursor to multiple myeloma. It is about determining who might benefit from testing, understanding individual progression risk, recognizing related conditions, and avoiding unnecessary intervention.
I also believe patients deserve access to research investigating nutrition, exercise, supplements, and other complementary approaches—as long as we distinguish preliminary findings from established medical benefits.
The goal should not be to screen everyone or treat every abnormal protein. The goal should be to identify clinically meaningful risk and respond appropriately.
Have you been diagnosed with MGUS? Was it discovered during routine blood testing or because of a specific medical concern?
Medical disclaimer: This article is educational and does not replace individualized evaluation or treatment recommendations from a qualified healthcare professional.
Diagnosed With MGUS? Why You Shouldn’t Just Watch and Wait
“The root cause of many cases of myeloma is monoclonal gammopathy of undetermined significance (MGUS), a blood disorder where white blood cells produce too much M protein. While MGUS does not present with many obvious signs of disease, the condition is easily detected through a blood test. So, identifying who should be screened for it can lead to earlier intervention for patients with myeloma, or possible prevention of the disease overall…
Why was it important for you and your team to conduct this research and find who is at high risk?
All multiple myeloma cases start with a stage called MGUS. Right now, there are no screening or other strategies to prevent multiple myeloma, and we wanted to know how we might one day help eradicate multiple myeloma by preventing it from developing in the first place.
The epidemiology of multiple myeloma tells us that disease risk varies with certain factors, such as gender, African ancestry and certain genes. Screening for MGUS is currently not performed regularly — this precursor stage is most often discovered by accident…
Is screening still important after a patient is diagnosed with myeloma?
No, after the diagnosis of multiple myeloma, treatment rather than screening is most important. However, after MGUS diagnosis, follow up screens to determine the individual patient’s rate of progression will be very important.
What is the grand takeaway you want to offer to our audience – patients, survivors and caregivers?
Tremendous advances in treatments for myeloma have turned it into a chronic disease with an improved quality of life and duration of survival. As researchers continue the search for cures, we want the community to know that we have opened a new front on the war against myeloma…”
APPIP ERROR: amazonproducts[
AccessDeniedAwsUsers|The Access Key Id AKIAJAJ37JVNL7OUU4CA is not enabled for accessing this version of Product Advertising API. Please migrate your credentials as referred here https://webservices.amazon.com/paapi5/documentation/migrating-your-product-advertising-api-account-from-your-aws-account.html.
]